about
Can megavoltage computed tomography reduce proton range uncertainties in treatment plans for patients with large metal implants?Is there an impact of heart exposure on the incidence of radiation pneumonitis? Analysis of data from a large clinical cohort.Determining the incident electron fluence for Monte Carlo-based photon treatment planning using a standard measured data set.Reference photon dosimetry data and reference phase space data for the 6 MV photon beam from varian clinac 2100 series linear accelerators.Displacement-based binning of time-dependent computed tomography image data sets.Design of respiration averaged CT for attenuation correction of the PET data from PET/CT.Four-dimensional cone beam CT with adaptive gantry rotation and adaptive data sampling.An efficient dose calculation strategy for intensity modulated proton therapy.Dosimetric benefits of robust treatment planning for intensity modulated proton therapy for base-of-skull cancers.Utility of four-dimensional computed tomography for analysis of intrafractional and interfractional variation in lung volumes.Impact of using different four-dimensional computed tomography data sets to design proton treatment plans for distal esophageal cancer.Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes.Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial.Exploration of the potential of liquid scintillators for real-time 3D dosimetry of intensity modulated proton beams.Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lunEvaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer.Stray radiation dose and second cancer risk for a pediatric patient receiving craniospinal irradiation with proton beams.The risk of developing a second cancer after receiving craniospinal proton irradiation.Contemporary Proton Therapy Systems Adequately Protect Patients from Exposure to Stray Radiation.An MCNPX Monte Carlo model of a discrete spot scanning proton beam therapy nozzleGenetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy.Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06.Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer.Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practiceLate rectal toxicity on RTOG 94-06: analysis using a mixture Lyman modelTechnical considerations in the application of intensity-modulated radiotherapy as a concomitant integrated boost for locally-advanced cervix cancer.Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer.Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer.Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers.Estimation of α/β for late rectal toxicity based on RTOG 94-06Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer.Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients.Robust optimization of intensity modulated proton therapy.Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment.New strategies in radiation therapy: exploiting the full potential of protons.Comprehensive analysis of proton range uncertainties related to patient stopping-power-ratio estimation using the stoichiometric calibrationEffects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer.Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer.Use of fractional dose-volume histograms to model risk of acute rectal toxicity among patients treated on RTOG 94-06.Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer
P50
Q28654979-1D0851BE-FF89-4C68-92D4-E2B084D46B15Q30664267-93CD2D7D-0801-4283-BF19-5A742FE82BDAQ30789916-A057D81C-C987-47AE-BD6F-359C6FC02A06Q30983094-F479302E-1022-432F-9E96-1E00DDE4ED7EQ31032572-FD627EC8-8F3F-4E4A-986D-F1453991CC2CQ31119864-838AF241-0627-4ECF-8E2E-97670E0800EEQ31132720-CE6065AF-0438-4F65-949E-6D20010FC0E7Q33274044-C85C7565-5D72-4919-9EF0-C46B2083C617Q33275432-3D7EE087-50FB-4A53-9AF9-8626594F5BE8Q33362709-B5664C55-187D-48F8-BACA-5AF76FE4E453Q33400176-8918EAAD-D3E8-4517-8F7F-9EB54C5CF459Q33615813-976A809E-C467-46AC-A75B-A928EB303CFFQ33645532-8EAA9A46-66DD-4D10-BD76-596B31FD8F07Q33703151-BF6038A0-AD50-4E9A-A88D-1B7EAD502D1CQ33843608-1853B9C4-3FF2-47FF-9247-29C698517C4CQ33860897-4ABA7812-14BD-4DFA-89CC-16D08ED5E358Q34081025-1DCE5B8B-8AF9-44D0-B8DC-F881694ACAB4Q34086830-236AB0B9-5CD6-422F-9FB8-6C1AA9976277Q34125730-2C046A55-8EF2-4160-92E6-8F8CA2885C52Q34137702-FB269856-356A-47F9-8679-FCF8862AA8FCQ34138157-B417342B-EFCB-4A6A-9FD8-53011FEB072CQ34161145-A052FD0A-5793-4426-9B64-7CE7A64222CEQ34187098-84107DFC-A958-45D7-AFE9-C4875F2A4D01Q34228231-C8573B54-27AC-4BBD-9AC7-F2C90F311F8DQ34238364-B96E6325-1870-42BB-BD1B-5BC39B1BDDDAQ34695886-D61A32D4-41CA-494E-B109-F6345D631589Q34739888-CD97F416-532C-4181-9C74-4B830152A451Q35050966-D9CE6891-FDCA-468F-BC0F-C8D11B1E5482Q35163969-CC787BDD-35FE-44DF-AF65-182AC134B394Q35186584-16BD47B6-3BAB-4901-AF6E-631D50D35ECCQ35216097-61E7F4E9-EE5E-419A-A437-AB5129D199FAQ35449770-B02F52F0-B6E4-41A9-9A32-DE9C6BB50947Q35764013-D12A1592-A93C-4E4A-8E26-A9DAD9452536Q35933778-526F834B-0EE7-4946-8320-882B132811DEQ35990699-C3031712-EA55-4237-A867-346ED869DDCEQ36094562-5FFA6F03-4D38-49A8-8DE1-3F038AB5D661Q36105956-D4DEA7D3-76F2-45E1-BF9C-873ACD64F7C6Q36133461-349CBDA6-915D-44DF-AF79-2DFF3C17AA51Q36145910-91C8118B-1C1A-4475-8EBF-44157972EBF3Q36151043-AC0F0E1F-E4B8-47CB-8258-30D79486775B
P50
description
American physicist
@en
fisico statunitense
@it
fisikari estatubatuarra
@eu
físic estatunidenc
@ca
físico estadounidense
@es
físico estadounidense
@gl
físico norte-americano
@pt
físicu estauxunidense
@ast
physicien américain
@fr
name
Radhe Mohan
@ast
Radhe Mohan
@ca
Radhe Mohan
@en
Radhe Mohan
@es
Radhe Mohan
@fr
Radhe Mohan
@nl
Radhe Mohan
@sl
type
label
Radhe Mohan
@ast
Radhe Mohan
@ca
Radhe Mohan
@en
Radhe Mohan
@es
Radhe Mohan
@fr
Radhe Mohan
@nl
Radhe Mohan
@sl
prefLabel
Radhe Mohan
@ast
Radhe Mohan
@ca
Radhe Mohan
@en
Radhe Mohan
@es
Radhe Mohan
@fr
Radhe Mohan
@nl
Radhe Mohan
@sl